CAS, the trusted source of scientific information solutions, has announced the formation of its CAS Life Sciences Advisory Board. The board, comprising esteemed thought leaders from renowned global research organizations, aims to advance drug discovery capabilities and workflows and guide the expanded CAS drug discovery journey.
With the goal of empowering better decisions in the early stages of drug discovery, the advisory board will align authoritative content with predictive technologies spanning the spectrum of life sciences workflows. This will include understanding disease progression with biological pathway data and assessing the effectiveness of exploratory drugs with enriched molecular biomarker data.
CAS is also recruiting additional members to ensure broad diversity and engagement.
CAS has already taken steps to accelerate early-stage drug discovery research with the expansion of content in the CAS Content CollectionTM in late 2022, which includes exhaustive biological sequences and bioactivity information. The collaboration with Chemotargets also leverages Clarity® to serve as a technology foundation for rapid development.
The formation of the CAS Life Sciences Advisory Board is a promising development in the scientific community, and we can expect exciting new advancements in the field of drug discovery in the years to come.
Click here to read the original press release.
